FDA Times FILSUVEZ Review for Patent Life Extension
Published Date: 12/10/2025
Notice
Summary
The FDA has officially set the review period for FILSUVEZ, a new drug, which helps the company extend its patent protection. This means the drug maker could get extra time to keep their invention exclusive, potentially affecting when generic versions can enter the market. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until early 2026 to speak up.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
FDA Sets FILSUVEZ Review Period
FDA determined the regulatory review period for FILSUVEZ is 1,929 days in total — 935 days in the testing phase and 994 days in the approval phase. Key dates used were: IND effective September 8, 2018 (FDA found; applicant claimed September 5, 2018), NDA initially submitted March 30, 2021, and NDA approval on December 18, 2023. This determination establishes the maximum potential length of a patent extension for this drug and could affect when generic versions can enter the market.
Company Seeks 1,463-Day Patent Extension
The patent applicant for FILSUVEZ is seeking 1,463 days of patent term extension; the FDA's determination sets the maximum potential extension but the U.S. Patent and Trademark Office will apply statutory limitations when calculating the actual extension awarded. If granted, the requested 1,463-day extension would extend the period of exclusivity before generics may enter the market.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
Previous / Next Documents
Previous: 2025-22379 — Revision of Agency Information Collection Activity Under OMB Review: Secure Flight Program
The TSA is updating how it collects passenger info from airlines to keep flights safe and spot potential threats. This affects U.S. and foreign airlines that share traveler details with the Secure Flight program. You’ve got until January 9, 2026, to share your thoughts, and no big cost changes are expected.
Next: 2025-22381 — Foreign-Trade Zone 40; Application for Subzone; Atlantic Veal & Lamb, LLC; Creston and Sterling, Ohio
Atlantic Veal & Lamb, LLC wants to join Foreign-Trade Zone 40 by adding two sites in Creston and Sterling, Ohio. This move could help the company save money on import taxes and speed up their business. Public comments are open until January 20, 2026, so folks have a chance to weigh in before the final decision.